Fezolinetant and Vascular Health and Brain Health

ClinicalTrials.gov ID

NCT07606664

Lead Sponsor

Rebecca ThurstonOTHER

Overall Status

Not yet recruiting

Study Type

Interventional

Phase

Phase 3

Enrollment

220Estimated

Last Update Posted

Aug 19, 2026Actual

Start Date

Sep 25, 2026Estimated

Primary Completion Date

Nov 30, 2029Estimated

Completion Date

Dec 30, 2029Estimated

Official Title

Fezolinetant and Vascular Health and Brain Health

Brief Summary

The goal of this clinical trial is to learn whether a study drug called fezolinetant impacts cardiovascular and cognitive health in women who have moderate to severe menopausal hot flashes and night sweats.

Researchers will compare fezolinetant to a placebo. A placebo is a pill that looks like the study drug but does not contain any active medicine. This comparison helps researchers understand whether fezolinetant works better than no treatment.

Participants will:

Be randomly assigned to take either fezolinetant (45 mg) or a placebo once a day for 12 weeks.

Visit the research clinic for regular checkups and tests during the study. Complete tests that measure blood vessel function and cognition.

Participants and study staff will not know which treatment each participant receives during the study.

Detailed Description

Double-blind, placebo-controlled randomized trial to determine whether 12 weeks of 45 mg of fezolinetant, a non-hormonal treatment for hot flashes associated with menopause, improves vascular and brain health in participants with moderate to severe menopausal hot flashes. Participants will be randomized to either 12 weeks of fezolinetant 45 mg or placebo. Primary endpoints include change from baseline in endothelial function and verbal memory.

• Menopause Hot Flashes

• Placebo
• Fezolinetant

Ages Eligible for Study

Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

Female

Accepts Healthy Volunteers

No

Eligibility Criteria

Inclusion Criteria:

• Born female
• Age ≥40 - ≤65 years at the time of the screening visit
• Body Mass Index (BMI) ≥18 to ≤38 kg/m2
• Seeking treatment or relief for moderate to severe VMS associated with menopause
• Confirmed menopausal as per one of the following criteria at the time of screening: Reporting spontaneous amenorrhea for ≥12 consecutive months; spontaneous amenorrhea for ≥6 and < 12 months with follicle-stimulating hormone >40 IU/L
• Negative urine pregnancy test at screening (if <12 months of amenorrhea)
• A minimum average of 7-8 moderate to severe VMS per day, or 50-60 per week prior to randomization as reported in the 7-day hot flash diary
• Agrees to not participate in another interventional study (pharmaceutical or device) while participating in this current study

Exclusion Criteria:

• Pregnancy/lactation (past 6 months)
• Any treatment for hot flashes with demonstrated efficacy for hot flashes
• Currently using systemic sex-hormone medications.
• Currently using cytochrome P450 1A2 (CYP1A2) inhibitors (as listed according to the FDA).
• Severely elevated blood pressure [systolic blood pressure (SBP) >180 and/or diastolic blood pressure (DBP) >110]
• A medical condition or chronic disease (including history of hepatic, renal, cardiovascular, gastrointestinal, pulmonary [e.g., moderate asthma], endocrine or gynecological disease) or malignancy that could confound interpretation of the study in the opinion of the investigator or study physician
• Self-reported narcolepsy
• Previous/current history of a malignant tumor, except for basal cell carcinoma
• Participants with known cirrhosis, active liver disease, jaundice, or elevated liver aminotransferases or total bilirubin (ALT, AST, and total bilirubin), should not be enrolled if ALT or AST is ≥ 2 x ULN or if the total bilirubin is ≥ 2 x ULN for the evaluating laboratory. Participants with ALP > 1.5 × ULN and judged clinically significant by the study physician.
• Severe renal impairment [estimated glomerular filtration rate (eGFR) 15 to <30 mL/min per 1.73 m2] or end-stage renal disease (ESRD) (eGFR < 15 mL/min/1.73 m2) at screening as per USPI
• Positive Hepatitis C virus antibody, Hepatitis B surface antigen, and/or human immunodeficiency virus antibody screen at screening
• History within the last 6 months of undiagnosed uterine bleeding
• Key medical conditions (history of cardiovascular disease, stroke/cerebrovascular accident, brain injury with loss of consciousness for more than 60 seconds within the last five years, cognitive disorders, brain tumor, dementia, Parkinson's disease, chemotherapy, psychotic disorders)
• Metal in the body, claustrophobia, or cannot undergo 3T magnetic resonance imaging (MRI); Inability to meet MRI eligibility criteria
• Lymph node removal on both sides of the body, mastectomy, or dialysis
• Hysterectomy; levonorgestrel-releasing intrauterine systems initiated before 12 months of spontaneous amenorrhea (Not exclusionary if placed after 12 months of spontaneous amenorrhea), or history of endometrial ablation will be excluded due to inability to stage menopause; Bilateral oophorectomy if completed prior to 12 months of spontaneous amenorrhea
• Cardiovascular medication use.
• Prior exposure to fezolinetant or elinzanetant
• Current participation in another interventional study or participated in an interventional study or received any investigational drug within 3 months
• Illicit substance use reported in the past week or detected by urine toxicology screen.
• Subject has any condition, which in the investigator's or study physician's opinion, makes the subject unsuitable for study participation.

Primary Purpose

Treatment

Allocation

Randomized

Interventional Model

Parallel Assignment

Masking

Triple

Lead Sponsor

Rebecca ThurstonOTHER

Collaborators

Astellas Pharma Global Development, Inc.INDUSTRY

conklinsm2@upmc.edu8782616899

• A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Chinese Women Going Through Menopause

  NCT06812754

  CompletedInterventionalPhase 2Updated Mar 19, 2026
• A Study to Find Out if Fezolinetant Helps Reduce Moderate to Severe Hot Flashes in Women in Asia Going Through Menopause

  NCT04234204

  CompletedInterventionalPhase 3Updated Jan 31, 2025
• A Study of Fezolinetant to Treat Hot Flashes in Women Going Through Menopause

  NCT05033886

  CompletedInterventionalPhase 3Updated Oct 26, 2024
• A Study to Find Out How Safe Long-term Treatment With Fezolinetant is in Women With Hot Flashes Going Through Menopause

  NCT04003389

  CompletedInterventionalPhase 3Updated Nov 5, 2024
• A Study to Find Out if Fezolinetant Helps Reduce Moderate to Severe Hot Flashes in Women Going Through Menopause - 2

  NCT04003142

  CompletedInterventionalPhase 3Updated Nov 5, 2024
• A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Japanese Women Going Through Menopause

  NCT06206408

  CompletedInterventionalPhase 3Updated Dec 23, 2025